Combination effects of herceptin, pertuzumab and bevacizumab in a HER2-overexpressing breast cancer xenograft model.
Bibliographic record
Abstract
Abstract Abstract #4058 Background: The HER2 receptor is overexpressed in 20-25% of breast cancer patients and is associated with poor prognosis. Trastuzumab, a humanized monoclonal antibody directed against the HER2 receptor, used alone or in combination with chemotherapy, has shown significant clinical benefit in improving survival in metastatic patients, as well as improving survival in early breast cancer. However, resistance to trastuzumab often develops within 1 year of treatment initiation. Recent studies have shown that trastuzumab in combination with pertuzumab or bevacizumab may have clinical benefit in selected HER2 overexpressing breast cancer patients. In the present study, we investigated whether blockade of HER homo- and heterodimer pairs in combination with an anti-VEGF, could more effectively inhibit tumor growth in a HER2 overexpressing breast cancer model. Material and Methods: Nude mice bearing subcutaneous BT474 HER2-R (a resistant derivative cell line) xenograft tumors were treated with trastuzumab (T) (10 or 20 mg/kg), pertuzumab (P) (15 mg/kg once weekly after an initial 30 mg/kg loading dose), bevacizumab (B) (5mg/kg), as single agents or in doublets and triplets combination therapies with T at 10 mg/kg. Endpoints include tumor volume, HER signaling, angiogenic biomarkers and occurrence of metastasis. Results: T (at its highest dose) and B, as single courses, showed significant anti-tumor activity as compared with the non-treated group. P or T (at its lowest dose) were not effective at inhibiting tumor growth. Combined treatment with P and B significantly inhibited tumor growth as compared with either agent alone or T alone. Time to tumor progression (tumors reaching 2.5 times baseline size) was 26 days for T + B & T + P, and 30 days for P+B as compared with 15 for P, 20 for H (20mg/kg) and 25 days for B, as single agents. In the mice treated with the triple combination, tumor volumes decreased after treatment initiation achieving a complete tumor regression on day 47 with no tumor regrowth up to day 80. Preliminary mechanistic studies showed that P and T as single agents or in combination caused a decrease of HER2 phosphorylation and downstream AKT activation. No further decrease of HER2 signaling was observed with the triple combination. Discussion: Our results confirm that inhibiting tumour angiogenesis by targeting VEGF has anti-tumor effects. Time to progression was delayed in mice treated with T+P compared with mice treated with a double dose of T, confirming that increasing the dosage of a single anti-HER agent is not as effective as using a combination regimen of inhibitors with different mechanisms of action. Complete tumor regression was achieved when B was combined with P and T at its lower dose, suggesting crosstalk between the VEGF pathway with both the epidermal growth factor receptor (EGFR) and HER2 pathways. Ongoing experiments, IHC and angiogenic biomarker analysis, will provide additional insight into the mechanism of action of T+P+B in this tumor model. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 4058.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".